808钱包APP

專注给予質高價優

的生物藥

科學論文

A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors
ASCO 2025
Serplulimab versus placebo plus chemotherapy as first line treatment for extensive stage small cell lung cancer: efficacy and safety from the end of study analysis of the international phase 3 ASTRUM 005 study
ASCO 2025
A randomized, double-blind, international phase 3 trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJC
ASCO 2025
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced/Metastatic Solid Tumors
ASCO 2025
Safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of HLX301, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors
ASCO 2025
ASTRUM 002: First Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Nonsquamous Non small Cell Lung Cance r
WCLC 2025

知識產權

專利申請數量	PCT申請數量	國內外授權專利數量	註冊司法權區	申請日期	到期日	發明專利數量
809	90	134	中國大陸	2011-03-18	2031-03-18	97